Why It Matters
The rise of autonomous laboratories — where artificial intelligence directs robotic systems to design and conduct experiments without human hands — is reshaping how scientific research gets done. Supporters say the shift could dramatically lower costs and accelerate discovery. Critics, including some of the field’s own researchers, warn the technology lowers barriers that once kept dangerous experiments out of untrained hands.
What Happened
Ginkgo Bioworks, a Boston-area biotechnology firm co-founded by four MIT graduate students, operates what it describes as a fully autonomous laboratory with views of Boston Harbor. Inside, robotic systems handle pipetting, sample management, and experiment execution — tasks traditionally performed by human scientists. An AI layer translates experimental blueprints into precise instructions the robots can carry out.
The company’s co-founders believed from the start that engineering biology would rival software development in long-term importance. Jason Kelly, one of the founders, has said: “We believed that programming cells would ultimately be more important than programming computers.”
Ginkgo has since collaborated with OpenAI, using ChatGPT to help design a protein synthesis workflow. According to the company, that AI-directed process cut costs by 40 percent compared to equivalent work done by humans. Over a six-month period, the system executed more than 30,000 individual experiments. The results have been published, though the paper has not yet undergone peer review.
Reshma Shetty, another of the company’s founders, described the moment the technology’s potential became visceral. “The really wild moment was the first time I saw a lab notebook entry written by the model,” she said.
Current projects at the facility include engineering microbes capable of producing fertilizer and developing proteins with applications in snow and ice management.
By the Numbers
- 4 — MIT graduate students who co-founded Ginkgo Bioworks
- 40% — cost reduction in protein synthesis achieved using ChatGPT-designed experiments versus human-led work
- 30,000+ — experiments completed by the autonomous system over six months
- 6 months — the timeframe in which those experiments were conducted
- 2014 — the year one founder read a Sam Altman blog post discussing the automation of biotechnology, which helped shape the company’s early vision
Zoom Out
The emergence of autonomous laboratories is part of a broader acceleration of AI’s role in technical and scientific fields. Algorithms are already reshaping how workers are scheduled and compensated across industries, and the technology’s reach is extending further into knowledge work that once required years of specialized training.
That expansion has drawn scrutiny beyond the business community. Drew Endy, a bioengineering professor at Stanford University, has raised concerns that AI-assisted laboratory platforms enable people without formal scientific training to run complex experiments. Endy and colleagues have published a report outlining potential risks associated with AI in biological research, including the possibility of mass-producing dangerous pathogens and broader biosecurity threats.
The Vatican recently weighed in on the societal implications of artificial intelligence from a different angle, with Pope Leo issuing a sweeping encyclical addressing AI’s ethical dimensions and the responsibilities of technology developers.
Early investors were reportedly skeptical of Ginkgo’s model when the company was getting off the ground, reflecting how novel the concept of a robot-run laboratory appeared even to those familiar with biotech. That hesitation has since given way to broader industry interest as the cost and speed advantages of autonomous systems have become more concrete.
What’s Next
The field faces a number of unresolved questions — among them, how peer review and scientific validation will adapt to research generated at scale by AI-directed systems. The Ginkgo-OpenAI protein synthesis findings, while published, have not cleared the peer-review process, leaving their full scientific standing uncertain.
Biosecurity experts and researchers like Endy are pressing for governance frameworks that address how autonomous laboratory platforms can be deployed responsibly. As the technology matures, regulatory bodies and research institutions will likely face increasing pressure to establish oversight standards for AI-directed scientific experimentation.